| Predicted Trait | |
| Reported Trait | Prostate cancer |
| Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
| Score Construction | |
| PGS Name | PRCA_PRSCS |
| Development Method | |
| Name | PRS-CS |
| Parameters | PRS-CS-auto, 1000G European sample (N = 503) as the external LD reference panel |
| Variants | |
| Original Genome Build | GRCh38 |
| Number of Variants | 1,102,292 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000562 |
| Citation (link to publication) | Youssef O et al. Lab Invest (2024) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 140,254 individuals (100%) |
| PGS Evaluation | European: 100% 1 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST006085 Europe PMC: 29892016 |
140,254 individuals | European | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM020696 | PSS011367| European Ancestry| 151,620 individuals |
PGP000562 | Youssef O et al. Lab Invest (2024) |
Reported Trait: Prostate cancer | OR: 2.13 [2.08, 2.17] | — | — | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011367 | — | — | [ ,
100.0 % Male samples |
— | European (Finnish) |
— | FinnGen | — |